Arch Biopartners Inc., of Toronto, noted that the scientific team that discovered Metablock, its peptide that blocks dipeptidase-1 (DPEP1), published a paper in Cell describing a novel mechanism action for inflammation-mediated organ injury involving the recruitment of neutrophils from the bloodstream into injured or infected organ tissues via DPEP1. In mice, genetic deletion and functional peptide inhibition of DPEP1 reduced neutrophil recruitment to the lungs and liver and also improved survival in models of sepsis.
In settling a contentious collaboration agreement from December 2014, a three-member arbitration panel ruled Eli Lilly and Co., of Indianapolis, acted appropriately regarding the intellectual property of Adocia SA, of Lyon, France, while denying Lilly's counterclaim that it is not liable for damages. Lilly had terminated the agreement and discontinued future development, manufacturing and commercialization of an insulin program with Adocia in January 2017.
Bioaegis Therapeutics Inc., of Morristown, N.J., published research demonstrating that recombinant human plasma gelsolin therapy improves survival in a multidrug-resistant pneumonia animal model. The therapy works synergistically with previously ineffective antibiotics. Results showed clinical improvement in mice infected with pneumococcal organisms even in the absence of antibiotic treatment and after delaying gelsolin administration. Plasma gelsolin supplementation also improved survival of animals challenged with penicillin-resistant microorganisms. The results were published in the Journal of Infectious Diseases.
Cantargia AB, of Stockholm, released preclinical data showing the molecular target for its antibody CAN-04 has been detected on cancer cells in approximately 80% of patients with bladder cancer. Cantargia said that statistically significant single agent activity was documented in an in vivo model of the disease. CAN-04 is being investigated in a phase IIa trial for non-small-cell lung cancer and pancreatic cancer. The company also extended its license agreement with Biowa Inc., of Princeton, N.J., to produce CAN-04.
Disarm Therapeutics Inc., of Cambridge, Mass., published two articles in Science about the structure and function of SARM1, a protein that helps regulate cellular degeneration. Both articles involve the centrality of the NAD+-cleavage pathway in mediating cellular degeneration across multiple species. Disarm is working on treatments for multiple sclerosis, amyotrophic lateral sclerosis, and peripheral neuropathies.
Errant Gene Therapeutics LLC, of Chicago, said the New York Supreme Court sanctioned Bluebird Bio Inc., of Cambridge, Mass, and rejected efforts to prevent Errant from proceeding with its lawsuit in Massachusetts against Bluebird CEO Nick Leschly and Bluebird's venture capital partner, Third Rock Ventures LLC. Following the court's decision, EGT served its complaint in Massachusetts against Leschly and Third Rock. Errant alleges the Sloan-Kettering Institute for Cancer Research and Bluebird intentionally abandoned Errant's gene therapy solely for Bluebird's benefit.
Hemispherx Biopharma Inc., of Ocala, Fla., will change its name to AIM Immunotech Inc. on Sept. 3. Its new ticker symbol will be AIM. The company is developing synergistic immunological agents for lethal cancers and severe myalgic encephalomyelitis/chronic fatigue syndrome.
Hotspot Therapeutics Inc., of Boston, acquired Macroceutics Inc., of Monmouth Junction, N.J., a provider of DNA-encoded library screening technologies. The deal is designed to enhance Hotspot's platform, which is designed to predict, drug and differentiate unique regulatory hotspots on proteins. The technology enables millions of molecules to be rapidly synthesized and screened against a protein of interest.
Oasmia Pharmaceutical AB, of Stockholm, delisted its American Depositary Shares from NASDAQ, to reduce complexity in financial reporting and administrative costs. Oasmia's ordinary shares continue to trade on Nasdaq Stockholm. The company will maintain an American Depositary Receipt facility to allow investors to hold Oasmia shares as American Depository Shares and to continue to trade those securities on the over-the-counter market.